用于口服给测试分子的载体对小鼠结核分枝杆菌感染进展的影响。
Influence of vehicles used for oral dosing of test molecules on the progression of Mycobacterium tuberculosis infection in mice.
机构信息
Drug Target Discovery and Development Division, Central Drug Research Institute, Lucknow, India.
出版信息
Antimicrob Agents Chemother. 2012 Nov;56(11):6026-8. doi: 10.1128/AAC.01702-12. Epub 2012 Aug 27.
Abstract
Preclinical evaluation of drug-like molecules requires their oral administration to experimental animals using suitable vehicles. We studied the effect of oral dosing with corn oil, carboxymethyl cellulose, dimethyl sulfoxide, and polysorbate-80 on the progression of Mycobacterium tuberculosis infection in mice. Infection was monitored by physical (survival time and body weight) and bacteriological (viable counts in lungs) parameters. Compared with water, corn oil significantly improved both sets of parameters, whereas the other vehicles affected only physical parameters.
摘要
在体药物评价需要用合适的载体对实验动物进行口服给药。我们研究了玉米油、羧甲基纤维素、二甲基亚砜和聚山梨酯 80 对感染结核分枝杆菌的小鼠进展的影响。通过生理（生存时间和体重）和细菌学（肺内活菌计数）参数监测感染情况。与水相比，玉米油显著改善了这两组参数，而其他载体仅影响生理参数。
相似文献
1
Influence of vehicles used for oral dosing of test molecules on the progression of Mycobacterium tuberculosis infection in mice.
Antimicrob Agents Chemother. 2012 Nov;56(11):6026-8. doi: 10.1128/AAC.01702-12. Epub 2012 Aug 27.
2
Effect of the bradykinin 1 receptor antagonist SSR240612 after oral administration in Mycobacterium tuberculosis-infected mice.
Tuberculosis (Edinb). 2018 Mar;109:1-7. doi: 10.1016/j.tube.2018.01.003. Epub 2018 Feb 2.
3
Therapeutic effects of traditional Chinese medicine Niubeixiaohe in mouse tuberculosis models.
J Ethnopharmacol. 2017 Jan 4;195:318-323. doi: 10.1016/j.jep.2016.11.037. Epub 2016 Nov 21.
4
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5198-207. doi: 10.1128/AAC.00826-16. Print 2016 Sep.
5
A new model for chronic and reactivation tuberculosis: Infection with genetically attenuated Mycobacterium tuberculosis in mice with polar susceptibility.
Tuberculosis (Edinb). 2018 Dec;113:130-138. doi: 10.1016/j.tube.2018.10.003. Epub 2018 Oct 10.
6
Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat.
Toxicology. 2009 Jun 30;261(1-2):47-58. doi: 10.1016/j.tox.2009.04.041. Epub 2009 May 3.
7
Aerosolized gentamicin reduces the burden of tuberculosis in a murine model.
Antimicrob Agents Chemother. 2012 Feb;56(2):883-6. doi: 10.1128/AAC.05633-11. Epub 2011 Dec 5.
8
Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.
Antimicrob Agents Chemother. 2012 Mar;56(3):1444-51. doi: 10.1128/AAC.00720-11. Epub 2011 Dec 12.
9
B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis.
J Immunol. 2007 Jun 1;178(11):7222-34. doi: 10.4049/jimmunol.178.11.7222.
10
In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Pharmacology. 2010;85(6):365-71. doi: 10.1159/000299795. Epub 2010 Jun 8.
引用本文的文献
1
Inhibition of Granuloma Triglyceride Synthesis Imparts Control of Through Curtailed Inflammatory Responses.
Front Immunol. 2021 Sep 15;12:722735. doi: 10.3389/fimmu.2021.722735. eCollection 2021.
2
Genistein Prevents Nitric Oxide Deficiency-Induced Cardiac Dysfunction and Remodeling in Rats.
Antioxidants (Basel). 2021 Feb 4;10(2):237. doi: 10.3390/antiox10020237.
3
Investigation of 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-chromen-2-one as a promising coumarin compound for the development of a new and orally effective antileishmanial agent.
Mol Biol Rep. 2020 Nov;47(11):8465-8474. doi: 10.1007/s11033-020-05887-5. Epub 2020 Oct 6.
本文引用的文献
1
Advancing the development of tuberculosis therapy.
Nat Rev Drug Discov. 2012 Mar 1;11(3):171-2. doi: 10.1038/nrd3694.
2
Polysorbates as novel lipid-modulating candidates for reducing serum total cholesterol and low-density lipoprotein levels in hyperlipidemic C57BL/6J mice and rats.
Eur J Pharmacol. 2011 Jun 25;660(2-3):468-75. doi: 10.1016/j.ejphar.2011.03.027. Epub 2011 Apr 2.
3
An oral Mycobacterium bovis BCG vaccine for wildlife produced in the absence of animal-derived reagents.
Clin Vaccine Immunol. 2009 Sep;16(9):1378-80. doi: 10.1128/CVI.00198-09. Epub 2009 Jul 1.
4
What animal models teach humans about tuberculosis.
Am J Respir Cell Mol Biol. 2008 Nov;39(5):503-8. doi: 10.1165/rcmb.2008-0154TR. Epub 2008 Jun 12.
5
Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
Adv Drug Deliv Rev. 2008 Mar 17;60(6):617-24. doi: 10.1016/j.addr.2007.10.012. Epub 2007 Nov 6.
6
Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2006 Apr;50(4):1245-50. doi: 10.1128/AAC.50.4.1245-1250.2006.
7
Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2004 Dec;48(12):4550-5. doi: 10.1128/AAC.48.12.4550-4555.2004.
8
Solubilizing excipients in oral and injectable formulations.
Pharm Res. 2004 Feb;21(2):201-30. doi: 10.1023/b:pham.0000016235.32639.23.
9
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.
Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):243-55. doi: 10.1007/s10096-004-1109-5. Epub 2004 Mar 13.
10
Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid.
Am Rev Respir Dis. 1960 Sep;82:295-313. doi: 10.1164/arrd.1960.82.3.295.
Zotero 插件